Multi-organic endocrine disrupting activity of the UV screen benzophenone 2 (BP2) in ovariectomized adult rats after 5 days treatment

被引:47
作者
Jarry, H [1 ]
Christoffel, J [1 ]
Rimoldi, G [1 ]
Koch, L [1 ]
Wuttke, W [1 ]
机构
[1] Univ Gottingen, Dept Clin & Expt Endocrinol, D-37075 Gottingen, Germany
关键词
BP2; multi-organic risk assessment; estrogen agonist; anti-thyroid action;
D O I
10.1016/j.tox.2004.06.040
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The chemical industry has developed Sun protection factor products, which contain a variety of so-called "UV screens", among others, benzophenones (BP). Based on the structure it can be assumed, that the variant BP2 may be a potent estrogenic endocrine disrupter (ED). Only very limited data are available in the literature about such action of BP2, which focussed on the uterotrophic effect in immature rats. However, determination of ED activity in the uterus is only a restricted approach with the potential risk of missing undesirable actions. Therefore, we examined a putative multiple organ ED activity of BP2 by measuring gene expression of marker genes in the uterus, liver, vagina and pituitary after 5 days oral application in adult ovariectornized (ovx) rats. An effect on lipid metabolism was assessed by determination of cholesterol, high- and low-density lipoproteins (HDL and LDL) in the blood. As control compound, estradiol (E2) was included in the study. A dose dependent E2-agonistic activity was observed in the uterus (increased weight), vagina (increased IGF1 expression), pituitary (reduced LH synthesis), liver (increased IGF1 expression) and lipid parameters (reduction). A non-E2-like action of BP2 was observed on T4- and T3-levels, which were significantly reduced. Except for the action of BP2 on thyroid hormone levels where it may inhibit thyroid peroxidase, this UV screen exerts clear E2-agonistic actions. Application of BP2 for 5 days proved to be a sufficient treatment period to unravel a multi-organic endocrine disrupting activity of this UV screen. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 21 条
[1]  
AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
[2]   Effects of proinflammatory cytokines on anterior pituitary 5′-deiodinase type I and type II [J].
Baur, A ;
Bauer, K ;
Jarry, H ;
Köhrle, J .
JOURNAL OF ENDOCRINOLOGY, 2000, 167 (03) :505-515
[3]   Dietary genistein inactivates rat thyroid peroxidase in vivo without an apparent hypothyroid effect [J].
Chang, HC ;
Doerge, DR .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2000, 168 (03) :244-252
[4]   Anti-thyroid isoflavones from soybean - Isolation, characterization, and mechanisms of action [J].
Divi, RL ;
Chang, HC ;
Doerge, DR .
BIOCHEMICAL PHARMACOLOGY, 1997, 54 (10) :1087-1096
[5]   Quantitative analysis of estrogen receptor-α and -β messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction [J].
Egawa, C ;
Miyoshi, Y ;
Iwao, K ;
Shiba, E ;
Noguchi, S .
ONCOLOGY, 2001, 61 (04) :293-298
[6]   Determination of benzophenone-3 and metabolites in water and human urine by solid-phase microextraction and quadrupole ion trap GC-MS [J].
Felix, T ;
Hall, BJ ;
Brodbelt, JS .
ANALYTICA CHIMICA ACTA, 1998, 371 (2-3) :195-203
[7]   IN-VITRO PROLACTIN BUT NOT LH AND FSH RELEASE IS INHIBITED BY COMPOUNDS IN EXTRACTS OF AGNUS-CASTUS - DIRECT EVIDENCE FOR A DOPAMINERGIC PRINCIPLE BY THE DOPAMINE-RECEPTOR ASSAY [J].
JARRY, H ;
LEONHARDT, S ;
GORKOW, C ;
WUTTKE, W .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY, 1994, 102 (06) :448-454
[8]   PHARMACOKINETICS OF BENZOPHENONE-3 AFTER ORAL-EXPOSURE IN MALE-RATS [J].
KADRY, AM ;
OKEREKE, CS ;
ABDELRAHMAN, MS ;
FRIEDMAN, MA ;
DAVIS, RA .
JOURNAL OF APPLIED TOXICOLOGY, 1995, 15 (02) :97-102
[9]   The OECD program to validate the rat uterotrophic bioassay. Phase 2: Dose-response studies [J].
Kanno, J ;
Onyon, L ;
Peddada, S ;
Ashby, J ;
Jacob, E ;
Owens, W .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2003, 111 (12) :1530-1549
[10]  
Kohrle J, 1988, Prog Clin Biol Res, V280, P323